The Claim
Twelve weeks of liraglutide or eight weeks of lixisenatide treatment does not alter plasma uric acid levels or urinary uric acid excretion in overweight adults with type 2 diabetes and normal baseline uric acid levels, despite weight loss and improved glycemic control.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In overweight adults with type 2 diabetes and normal uric acid levels, treatment with liraglutide for 12 weeks or lixisenatide for 8 weeks does not change the amount of uric acid in the blood or excreted in urine, even when weight decreases and blood sugar improves.
See the scientific wording
Twelve weeks of liraglutide or eight weeks of lixisenatide treatment does not alter plasma uric acid levels or urinary uric acid excretion in overweight adults with type 2 diabetes and normal baseline uric acid levels, despite weight loss and improved glycemic control.
When GLP-1 drugs act on the kidneys, they make the urine less acidic and cause more sodium to be flushed out, which should push more uric acid out too. But at the same time, these drugs trigger the pancreas to release more insulin, and that insulin pulls uric acid back into the blood from the kidneys. The insulin effect cancels out the uric acid flushing, so overall uric acid levels in the blood and urine stay the same.
What the research says
1 studyEven though these diabetes drugs help people lose weight and lower blood sugar, they don’t change how much uric acid is in the blood or passed out in urine — the study found no difference after months of use.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.